Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792463 · ClinicalTrials.gov registry record
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
A clinical trial of Hepatocellular Carcinoma and Renal Cell Carcinoma, sponsored by Mohamed Abdel-Rahman.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04792463 is a study of Hepatocellular Carcinoma and Renal Cell Carcinoma that is actively recruiting participants, run by Mohamed Abdel-Rahman. The registered enrollment target is 500 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04792463, a study of Hepatocellular Carcinoma and Renal Cell Carcinoma, is actively recruiting participants, sponsored by Mohamed Abdel-Rahman.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.
Conditions Studied
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792463
The ClinicalTrials.gov registry entry for NCT04792463 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher). The listed sponsor is Mohamed Abdel-Rahman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04792463 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04792463 about?
NCT04792463 is a clinical study titled "Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome". This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strat...
What is the current status of trial NCT04792463?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2015-03-03. Estimated completion is 2026-07-01.
What conditions does trial NCT04792463 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Renal Cell Carcinoma, Cholangiocarcinoma, Mesothelioma, Cutaneous Melanoma.
Who is sponsoring clinical trial NCT04792463?
This trial is sponsored by Mohamed Abdel-Rahman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792463 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.